EcoDrugPlus

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSDCDG00000035907
Gene Symbol: LOC114764886
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSDCDG00000030848
Gene Symbol: LOC114801049
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSDCDG00000030172
Gene Symbol: LOC114800362
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSDCDG00000020132
Gene Symbol: LOC114798153
2 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSDCDG00000004179
Gene Symbol: MAPK8
3 Cross references
223 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSDCDG00000023657
Gene Symbol: MAPK9
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSDCDG00000032785
Gene Symbol: MAP2K1
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSDCDG00000022451
Gene Symbol: MAP2K2
3 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSDCDG00000028034
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSDCDG00000034385
Gene Symbol: MAP3K10
3 Cross references
181 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSDCDG00000017731
Gene Symbol: MAP3K11
3 Cross references
181 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSDCDG00000032712
Gene Symbol: MAP3K12
3 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).